0001209191-17-055918.txt : 20171004
0001209191-17-055918.hdr.sgml : 20171004
20171004170100
ACCESSION NUMBER: 0001209191-17-055918
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171002
FILED AS OF DATE: 20171004
DATE AS OF CHANGE: 20171004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chodakewitz Jeffrey
CENTRAL INDEX KEY: 0001610876
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 171122307
MAIL ADDRESS:
STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC.
STREET 2: 480 ARSENAL ST., SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-02
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001610876
Chodakewitz Jeffrey
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP GMDA, CMO
Common Stock
2017-10-02
4
M
0
3437
73.51
A
117861
D
Common Stock
2017-10-02
4
S
0
1394
151.04
D
116467
D
Common Stock
2017-10-02
4
S
0
1443
151.82
D
115024
D
Common Stock
2017-10-02
4
S
0
600
152.62
D
114424
D
Stock Option (Right to Buy)
73.51
2017-10-02
4
M
0
3437
0.00
D
2024-01-01
Common Stock
3437
3438
D
Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $151.04 (range $150.37 to $151.36).
Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $151.82 (range $151.47 to $152.18).
Open market sales reported on this line occurred at a weighted average price of $152.62 (range $152.54 to $152.70).
The option vests in 16 quarterly installments from 1/2/2014.
/s/ Omar White, Attorney-in-Fact
2017-10-04